CBD Life Sciences Inc.
CBDL · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -34.9% | 4.3% | 170.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9.1% | -18.3% | -174.9% | -250.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $1 | $0 | $1 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $4 |
| Other Operating Expenses | $0 | $0 | $0 | -$1 |
| Operating Expenses | $1 | $0 | $1 | $5 |
| Operating Income | -$1 | -$0 | -$1 | -$5 |
| % Margin | -695.4% | -47% | -536.6% | -8,654.2% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$1 | -$0 | -$1 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$0 | -$1 | -$5 |
| % Margin | -695.4% | -47% | -536.6% | -8,654.2% |
| EPS | -0 | -0.001 | -0 | -0 |
| % Growth | 66.7% | -200% | 50% | – |
| EPS Diluted | -0 | -0.001 | -0 | -0 |
| Weighted Avg Shares Out | 3,097 | 136 | 4,071 | 1,230 |
| Weighted Avg Shares Out Dil | 3,097 | 136 | 4,071 | 1,230 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$0 | -$1 | -$5 |
| % Margin | -644.3% | -13.8% | -503.1% | -8,255% |